CareDx Q1 Revenue Up 39% to $118M and Acquires Naveris for $260M
CareDx posted Q1 revenue of $118 million, up 39%, led by a 48% jump in testing services to $91 million and adjusted EBITDA rising over 300% to $19 million. It raised 2026 revenue guidance to $447–$465 million, authorized a $100 million buyback and will acquire Naveris for $260 million.
1. Q1 Financial Results
CareDx reported Q1 total revenue of $118 million, up 39% year-over-year, driven by a 48% increase in testing services revenue to $91 million and a 17% rise in test volume to 54,900. Adjusted EBITDA soared over 300% to $19 million, and GAAP net income reached $3 million.
2. 2026 Guidance and Buyback Program
The company raised its full-year 2026 revenue guidance to $447 million–$465 million, indicating 20% growth at the midpoint, and set adjusted EBITDA guidance at $43 million–$57 million, a 58% increase year-over-year. It also authorized a $100 million share repurchase program over the next 24 months.
3. Naveris Acquisition
CareDx agreed to acquire Naveris for up to $260 million to expand into cancer minimal residual disease testing. The deal adds Naveris’s NavDx liquid biopsy platform for monitoring HPV-driven cancers and strengthens CareDx’s presence in specialty oncology diagnostics.